The Evolving Battle Against Gram-Negative Infections: Rethinking Antibiotic Stewardship
The emergence of recent beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations is reshaping the treatment of multidrug-resistant Gram-negative infections, but innovation alone isn’t enough. Hospital pharmacists are facing a critical need to rethink when and how these agents are deployed, moving beyond traditional restriction-based stewardship to a more nuanced, evidence-driven approach.
A Global Threat Escalates
Antimicrobial resistance (AMR) is a “supreme global threat,” according to Professor Andrew Seaton, president of the British Society for Antimicrobial Chemotherapy (BSAC). Globally, AMR was linked to 1.14 million deaths in 2021. The situation is equally concerning within the UK, with drug-resistant bacteraemia increasing by 13.1% between 2019 and 2024. Enterobacterales, particularly Escherichia coli and Klebsiella pneumoniae, are the primary drivers of this rise.
The Promise of New BL/BLI Combinations
Development efforts are heavily focused on BL/BLI combinations. Cefepime/enmetazobactam offers stability against certain enzymes, potentially sparing carbapenem use in some cases. Avibactam, paired with aztreonam, shows particular promise against metallo-beta-lactamase (MBL) producers, restoring activity across multiple classes. Sulbactam/durlobactam addresses resistance in Acinetobacter baumannii, while vaborbactam, with meropenem, extends activity against KPC and AmpC producers.
Beyond Restriction: A New Stewardship Dilemma
While these new agents offer a significant advantage, simply having them available isn’t enough. Dr. Ryan Shields, of the University of Pittsburgh Medical Center, highlights a “stewardship dilemma”: balancing timely access to life-saving drugs with the need to preserve their effectiveness. Data suggests that newer antibiotics, like ceftazidime/avibactam and meropenem/vaborbactam, are associated with improved mortality rates in specific infections, particularly those caused by KPC-producing organisms.
Optimizing Drug Delivery for Maximum Impact
Traditional antibiotic delivery methods are being challenged. As time-dependent beta-lactams, drugs like ceftazidime/avibactam require sustained exposure. Prolonged infusion is recommended to maximize effectiveness. A large Italian study demonstrated lower mortality rates in patients receiving ceftazidime/avibactam via prolonged infusion. Surprisingly, the study also found higher mortality in patients undergoing standard renal dose adjustments, suggesting that avoiding underexposure is crucial, even in the context of transient kidney injury.
Pro Tip: Consider intensive therapeutic drug monitoring and multidisciplinary oversight to ensure patients achieve optimal pharmacokinetic-pharmacodynamic targets.
The Challenge of Pseudomonas aeruginosa
Deploying new agents is particularly complex when dealing with Pseudomonas aeruginosa. The lack of rapid diagnostic tests for its diverse resistance mechanisms, coupled with its remarkable adaptive capacity, presents a significant challenge. Resistance to ceftazidime/avibactam and ceftolozane/tazobactam has been observed in approximately one in five patients during therapy. Delaying treatment until salvage scenarios may reduce the effectiveness of these agents, as the organism may have already developed multiple resistance mechanisms.
Future Stewardship: Strategic Deployment
The BSAC New Agents conference underscored that the success of new antibiotics depends on several factors: early pathogen detection, optimized drug exposure, and strategic integration into treatment pathways. Stewardship must evolve from cautious restriction to a more proactive, evidence-based approach. This includes considering earlier treatment selection and potentially adjusting treatment strategies based on evolving resistance patterns.
FAQ
Q: What are BL/BLI combinations?
A: Beta-lactam/beta-lactamase inhibitor combinations are a class of antibiotics designed to overcome resistance mechanisms in Gram-negative bacteria.
Q: Why is optimizing drug delivery important?
A: Ensuring adequate drug exposure is crucial for maximizing the effectiveness of antibiotics and minimizing the development of resistance.
Q: What is the role of pharmacists in antimicrobial stewardship?
A: Pharmacists play a vital role in ensuring appropriate antibiotic use, optimizing drug delivery, and monitoring for resistance.
Q: Is antimicrobial resistance a growing problem?
A: Yes, antimicrobial resistance is a significant and growing global health threat, leading to increased morbidity and mortality.
Did you recognize? The pipeline for new antibiotics remains weak, highlighting the urgent need for continued innovation in antimicrobial development.
Want to learn more about combating antimicrobial resistance? Explore the World Health Organization’s resources on AMR.
